Allspring Global Investments Holdings LLC Sells 1,772,112 Shares of ADMA Biologics Inc $ADMA

Allspring Global Investments Holdings LLC decreased its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 53.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,548,139 shares of the biotechnology company’s stock after selling 1,772,112 shares during the period. Allspring Global Investments Holdings LLC owned about 0.65% of ADMA Biologics worth $23,299,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Cullen Frost Bankers Inc. boosted its position in shares of ADMA Biologics by 112.5% during the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,081 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in ADMA Biologics during the second quarter valued at $46,000. Toth Financial Advisory Corp boosted its holdings in shares of ADMA Biologics by 1,081.6% during the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 2,293 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,180 shares in the last quarter. Finally, Blue Trust Inc. grew its position in shares of ADMA Biologics by 53.6% in the 2nd quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock worth $50,000 after buying an additional 964 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Down 2.0%

NASDAQ:ADMA opened at $17.88 on Friday. The stock has a market cap of $4.26 billion, a price-to-earnings ratio of 20.79 and a beta of 0.47. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The company’s 50 day moving average price is $17.77 and its 200-day moving average price is $17.12.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business had revenue of $134.22 million for the quarter, compared to the consensus estimate of $131.20 million. During the same period last year, the business posted $0.15 EPS. The company’s revenue was up 12.0% compared to the same quarter last year. On average, equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.